W. Akahata and G. J. Nabel, A specific domain of the chikungunya virus E2 protein regulates particle formation in human cells: Implications for alphavirus vaccine design, J Virol, vol.86, pp.8879-8883, 2012.

W. Akahata, Z. Y. Yang, H. Andersen, and S. Sun, A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection, Nat Med, vol.16, pp.334-338, 2010.

I. C. Albulescu, A. Tas, F. E. Scholte, and E. J. Snijder, An in vitro assay to study chikungunya virus RNA synthesis and the mode of action of inhibitors, J Gen Virol, 2014.

P. M. Allard, P. Leyssen, M. T. Martin, and M. Bourjot, Antiviral chlorinated daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri, Phytochemistry, vol.84, pp.160-168, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00769790

H. Bao, A. A. Ramanathan, O. Kawalakar, and S. G. Sundaram, Nonstructural protein 2 (nsP2) of chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA vaccine, Viral Immunol, vol.26, pp.75-83, 2013.

M. Bassetto, D. Burghgraeve, T. Delang, L. Massarotti, and A. , Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus, Antiviral Res, vol.98, pp.12-18, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01054208

W. A. Boere, B. J. Benaissa-trouw, M. Harmsen, and C. A. Kraaijeveld, Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis, J Gen Virol, vol.64, pp.1405-1408, 1983.

L. Both, A. C. Banyard, C. Van-dolleweerd, and E. Wright, Monoclonal antibodies for prophylactic and therapeutic use against viral infections, Vaccine, vol.31, pp.1553-1559, 2013.

M. Bourjot, L. Delang, V. H. Nguyen, and J. Neyts, Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of chikungunya virus replication, J Nat Prod, vol.75, pp.2183-2187, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00785632

S. Brandler, C. Ruffie, C. Combredet, and J. B. Brault, A recombinant measles vaccine expressing chikungunya viruslike particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus, Vaccine, vol.31, pp.3718-3725, 2013.

S. Briolant, D. Garin, N. Scaramozzino, and A. Jouan, In vitro inhibition of chikungunya and Semliki Forest viruses replication by antiviral compounds: Synergistic effect of interferon-alpha and ribavirin combination, Antiviral Res, vol.61, pp.111-117, 2004.

F. J. Burt, M. S. Rolph, N. E. Rulli, and S. Mahalingam, Chikungunya: A re-emerging virus, Lancet, vol.379, pp.662-671, 2012.

A. Chattopadhyay, E. Wang, R. Seymour, and S. C. Weaver, A chimeric vesiculo/alphavirus is an effective alphavirus vaccine, J Virol, vol.87, pp.395-402, 2013.

H. Chu, S. C. Das, J. F. Fuchs, and M. Suresh, Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against chikungunya in the A129 mouse model, Vaccine, vol.31, pp.3353-3360, 2013.

T. Couderc, N. Khandoudi, M. Grandadam, and C. Visse, Prophylaxis and therapy for chikungunya virus infection, J Infect Dis, vol.200, pp.516-523, 2009.

D. J. Cruz, R. M. Bonotto, R. G. Gomes, and C. T. Da-silva, Identification of novel compounds inhibiting chikungunya virusinduced cell death by high throughput screening of a kinase inhibitor library, PLoS Negl Trop Dis, vol.7, p.2471, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01108617

X. De-lamballerie, V. Boisson, J. C. Reynier, and S. Enault, On chikungunya acute infection and chloroquine treatment, Vector Borne Zoonotic Dis, vol.8, pp.837-839, 2008.

L. Delang, J. Neyts, I. Vliegen, and S. Abrignani, Hepatitis C virus-specific directly acting antiviral drugs, Curr Top Microbiol Immunol, vol.369, pp.289-320, 2013.

L. Delang, S. Guerrero, N. Tas, A. Querat, and G. , Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral, J Antimicrobiol Chemother, vol.69, pp.2770-2784, 2014.

I. Delogu, B. Pastorino, C. Baronti, and A. Nougairede, In vitro antiviral activity of arbidol against chikungunya virus and characteristics of a selected resistant mutant, Antiviral Res, vol.90, pp.99-107, 2011.

J. L. Demeio, A. N. Desanctis, and W. J. Thomas, Persistence in humans of antibody after immunization with four alphavirus vaccines, Asian J Infect Dis, vol.3, pp.119-124, 1979.

S. K. Dessain, S. P. Adekar, and J. D. Berry, Exploring the native human antibody repertoire to create antiviral therapeutics, Curr Top Microbiol Immunol, vol.317, pp.155-183, 2008.

R. Edelman, C. O. Tacket, S. S. Wasserman, and S. A. Bodison, Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218, Am J Trop Med Hyg, vol.62, pp.681-685, 2000.

J. Fric, S. Bertin-maghit, C. I. Wang, and A. Nardin, Use of human monoclonal antibodies to treat chikungunya virus infection, J Infect Dis, vol.207, pp.319-322, 2013.

Y. Furuta, B. B. Gowen, K. Takahashi, and K. Shiraki, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, vol.100, pp.446-454, 2013.

J. Garcia-arriaza, V. Cepeda, D. Hallengärd, and C. O. Sorzano, A novel poxvirus-based vaccine (MVA-CHIKV) is highly immunogenic and protects mice against chikungunya infection, J Virol, vol.88, pp.3527-3547, 2014.

P. Gerardin, G. Barau, A. Michault, and M. Bintner, Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion, PLoS Med, vol.5, p.60, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00700815

L. Y. Goh, J. Hobson-peters, N. A. Prow, and J. Gardner, Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model, Clin Immunol, vol.149, pp.487-497, 2013.

A. Golubtsov, L. Kaariainen, and J. Caldentey, Characterization of the cysteine protease domain of Semliki Forest virus replicase protein nsP2 by in vitro mutagenesis, FEBS Lett, vol.580, pp.1502-1508, 2006.

C. E. Gómez, J. L. Nájera, M. Krupa, and B. Perdiguero, MVA and NYVAC as vaccines against emergent infectious diseases and cancer, Curr Gene Ther, vol.11, pp.189-217, 2011.

R. Gorchakov, E. Wang, G. Leal, and N. L. Forrester, Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein, J Virol, vol.86, pp.6084-6096, 2012.

D. Hallengärd, M. Kakoulidou, A. Lulla, and B. M. Kummerer, Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice, J Virol, vol.88, pp.2858-2866, 2014.

D. Hallengärd, F. Lumb, B. M. Kümmerer, and A. Lulla, Prime-boost immunization strategies against chikungunya virus, J Virol, vol.88, pp.13333-13343, 2014.

V. R. Harrison, K. H. Eckels, P. J. Bartelloni, and C. Hampton, Production and evaluation of a formalin-killed chikungunya vaccine, J Immunol, vol.107, pp.643-647, 1971.

C. H. Hoke, J. Pace-templeton, P. Pittman, and F. J. Malinoski, US Military contributions to the global response to pandemic chikungunya, Vaccine, vol.30, pp.6713-6720, 2012.

Y. W. Kam, W. W. Lee, D. Simarmata, and S. Harjanto, Longitudinal analysis of the human antibody response to chikungunya virus infection: Implications for serodiagnosis and vaccine development, J Virol, vol.86, pp.13005-13015, 2012.

Y. W. Kam, F. M. Lum, T. H. Teo, and W. W. Lee, Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein, EMBO Mol Med, vol.4, pp.330-343, 2012.

Y. W. Kam, D. Simarmata, A. Chow, and Z. Her, Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection, J Infect Dis, vol.205, pp.1147-1154, 2012.

P. Kaur and J. J. Chu, Chikungunya virus: An update on antiviral development and challenges, Drug Discov Today, vol.18, pp.969-983, 2013.

M. Khan, S. R. Santhosh, M. Tiwari, L. Rao, and P. V. , Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells, J Med Virol, vol.82, pp.817-824, 2010.

M. Khan, R. Dhanwani, I. K. Patro, and P. V. Rao, Cellular IMPDH enzyme activity is a potential target for the inhibition of chikungunya virus replication and virus induced apoptosis in cultured mammalian cells, Antiviral Res, vol.89, pp.1-8, 2011.

M. Khan, R. Dhanwani, P. V. Rao, and M. Parida, Subunit vaccine formulations based on recombinant envelope proteins of chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice, Virus Res, vol.167, pp.236-246, 2012.

R. M. Kramer, Y. Zeng, N. Sahni, and L. A. Kueltzo, Development of a stable virus-like particle vaccine formulation against chikungunya virus and investigation of the effects of polyanions, J Pharm Sci, vol.102, pp.4305-4314, 2013.

M. Kumar, A. B. Sudeep, and V. A. Arankalle, Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus, Vaccine, vol.30, pp.6142-6149, 2012.

A. Lampio, T. Ahola, E. Darzynkiewicz, and J. Stepinski, Guanosine nucleotide analogs as inhibitors of alphavirus mRNA capping enzyme, Antiviral Res, vol.42, pp.35-46, 1999.

C. Y. Lee, Y. W. Kam, J. Fric, and B. Malleret, Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants, PLoS Pathog, vol.7, p.1002390, 2011.

N. H. Levitt, H. H. Ramsburg, S. E. Hasty, and P. M. Repik, Development of an attenuated strain of chikungunya virus for use in vaccine production, Vaccine, vol.4, pp.157-162, 1986.

J. Magden, L. Kaariainen, and T. Ahola, Inhibitors of virus replication: Recent developments and prospects, Appl Microbiol Biotechnol, vol.66, pp.612-621, 2005.

K. Mallilankaraman, D. J. Shedlock, H. Bao, and O. U. Kawalekar, A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates, PLoS Negl Trop Dis, vol.5, p.928, 2011.

M. P. Manns and T. Von-hahn, Novel therapies for hepatitis C: one pill fits all?, Nat Rev Drug Discov, vol.12, pp.595-610, 2013.

J. H. Mathews, J. T. Roehrig, and D. W. Trent, Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoproteinspecific monoclonal antibodies, J Virol, vol.55, pp.594-600, 1985.

D. J. Mcclain, P. R. Pittman, H. H. Ramsburg, and G. O. Nelson, Immunologic interference from sequential administration of live attenuated alphavirus vaccines, J Infect Dis, vol.177, pp.634-641, 1998.

S. W. Metz, C. Geertsema, B. E. Martina, and P. Andrade, Functional processing and secretion of chikungunya virus E1 and E2 glycoproteins in insect cells, Virol J, vol.8, p.353, 2011.

S. W. Metz, J. Gardner, C. Geertsema, and T. T. Le, Effective chikungunya virus-like particle vaccine produced in insect cells, PLoS Negl Trop Dis, vol.7, p.2124, 2013.

S. W. Metz, B. E. Martina, P. Van-den-doel, and C. Geertsema, Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits, Vaccine, vol.31, pp.6092-6096, 2013.

K. Muthumani, K. M. Lankaraman, D. J. Laddy, and S. G. Sundaram, Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus, Vaccine, vol.26, pp.5128-5134, 2008.

P. Pal, K. A. Dowd, J. D. Brien, and M. A. Edeling, Development of a highly protective combination monoclonal antibody therapy against chikungunya virus, PLoS Pathog, vol.9, p.1003312, 2013.

C. D. Partidos, J. Paykel, J. Weger, and E. M. Borland, Crossprotective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine, Vaccine, vol.30, pp.4638-4643, 2012.

A. Piper, M. Ribeiro, K. M. Smith, and C. M. Briggs, Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice, J Virol, vol.87, pp.6748-6457, 2013.

K. Plante, E. Wang, C. D. Partidos, and J. Weger, Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism, PLoS Pathog, vol.7, p.1002142, 2011.

L. Pohjala, S. Alakurtti, T. Ahola, and J. Yli-kauhaluoma, Betulin-derived compounds as inhibitors of alphavirus replication, J Nat Prod, vol.72, pp.1917-1926, 2009.

L. Pohjala, A. Utt, M. Varjak, and A. Lulla, Inhibitors of alphavirus entry and replication identified with a stable chikungunya replicon cell line and virus-based assays, PLoS One, vol.6, p.28923, 2011.

A. P. Rathore, T. Haystead, P. K. Das, and A. Merits, Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus 256

, Downloaded by Institut Pasteur from www.liebertpub.com at 01/22/20. For personal use only. replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo, Antiviral Res, vol.103, pp.7-16, 2014.

C. J. Roy, A. P. Adams, E. Wang, and K. Plante, Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose, J Infect Dis, vol.209, pp.1891-1899, 2014.

J. K. Rubach, B. R. Wasik, J. C. Rupp, and R. J. Kuhn, Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro, Virology, vol.384, pp.201-208, 2009.

L. M. Scheidel and V. Stollar, Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1, Virology, vol.181, pp.490-499, 1991.

A. L. Schmaljohn, K. M. Kokubun, and G. A. Cole, Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein, Virology, vol.130, pp.144-154, 1983.

F. E. Scholte, A. Tas, B. E. Martina, and P. Cordioli, Characterization of synthetic chikungunya viruses based on the consensus sequence of recent E1-226V isolates, PLoS One, vol.8, p.71047, 2013.

S. Selvarajah, N. R. Sexton, K. M. Kahle, and R. H. Fong, A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease, PLoS Negl Trop Dis, vol.7, p.2423, 2013.

D. Singh-kh, P. Kirubakaran, S. Nagarajan, and S. Sakkiah, Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of chikungunya virus nsP2 protease, J Mol Model, vol.18, pp.39-51, 2012.

S. Sun, Y. Xiang, W. Akahata, and H. Holdaway, Structural analyses at pseudo atomic resolution of chikungunya virus and antibodies show mechanisms of neutralization, Elife, vol.2, p.435, 2013.

M. Tiwari, M. Parida, S. R. Santhosh, and M. Khan, Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus, Vaccine, vol.27, pp.2513-2522, 2009.

I. Tretyakova, J. Hearn, E. Wang, and S. Weaver, DNA Vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice, J Infect Dis, vol.209, pp.1882-1890, 2014.

A. Volz and G. Sutter, Protective efficacy of modified vaccinia virus Ankara in preclinical studies, Vaccine, vol.31, pp.4235-4240, 2013.

J. Wagner, J. D. Pajerowski, C. L. Daniels, and P. M. Mchugh, Enhanced production of chikungunya virus-like particles using a high-pH adapted Sprodotera frugiperda insect cell line, PLoS One, vol.10, p.1371, 2014.

D. Wang, A. Suhrbier, A. Penn-nicholson, and J. Woraratanadharm, A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis, Vaccine, vol.29, pp.2803-2809, 2011.

E. Wang, E. Volkova, A. P. Adams, and N. Forrester, Chimeric alphavirus vaccine candidates for chikungunya, Vaccine, vol.26, pp.5030-5039, 2008.

E. Wang, D. Y. Kim, S. C. Weaver, and I. Frolov, Chimeric chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response, J Virol, vol.85, pp.9249-9252, 2011.

S. C. Weaver, J. E. Osorio, J. A. Livengood, and R. Chen, Chikungunya virus and prospects for a vaccine, Expert Rev Vaccines, vol.11, pp.1087-1101, 2012.